201 related articles for article (PubMed ID: 30926773)
1. Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies.
Hobson JJ; Al-Khouja A; Curley P; Meyers D; Flexner C; Siccardi M; Owen A; Meyers CF; Rannard SP
Nat Commun; 2019 Mar; 10(1):1413. PubMed ID: 30926773
[TBL] [Abstract][Full Text] [Related]
2. Injectable long-acting human immunodeficiency virus antiretroviral prodrugs with improved pharmacokinetic profiles.
Krovi SA; Gallovic MD; Keller AM; Bhat M; Tiet P; Chen N; Collier MA; Gurysh EG; Pino EN; Johnson MM; Shamim Hasan Zahid M; Cottrell ML; Pirone JR; Kashuba AD; Kwiek JJ; Bachelder EM; Ainslie KM
Int J Pharm; 2018 Dec; 552(1-2):371-377. PubMed ID: 30308272
[TBL] [Abstract][Full Text] [Related]
3. Linear and branched polymer prodrugs of the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine as structural materials for long-acting implants.
Shakil A; Hern FY; Liu C; Temburnikar K; Chambon P; Liptrott N; McDonald TO; Neary M; Owen A; Freel Meyers C; Rannard SP
J Mater Chem B; 2022 Jun; 10(23):4395-4404. PubMed ID: 35604111
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of a long acting nanoformulated emtricitabine ProTide.
Soni D; Bade AN; Gautam N; Herskovitz J; Ibrahim IM; Smith N; Wojtkiewicz MS; Dyavar Shetty BL; Alnouti Y; McMillan J; Gendelman HE; Edagwa BJ
Biomaterials; 2019 Nov; 222():119441. PubMed ID: 31472458
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in long-acting nanoformulations for delivery of antiretroviral drugs.
Surve DH; Jindal AB
J Control Release; 2020 Aug; 324():379-404. PubMed ID: 32461114
[TBL] [Abstract][Full Text] [Related]
6. Short Communication: Comparative Evaluation of Coformulated Injectable Combination Antiretroviral Therapy Regimens in Simian Immunodeficiency Virus-Infected Rhesus Macaques.
Del Prete GQ; Smedley J; Macallister R; Jones GS; Li B; Hattersley J; Zheng J; Piatak M; Keele BF; Hesselgesser J; Geleziunas R; Lifson JD
AIDS Res Hum Retroviruses; 2016 Feb; 32(2):163-8. PubMed ID: 26150024
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticle-in-microparticle oral drug delivery system of a clinically relevant darunavir/ritonavir antiretroviral combination.
Augustine R; Ashkenazi DL; Arzi RS; Zlobin V; Shofti R; Sosnik A
Acta Biomater; 2018 Jul; 74():344-359. PubMed ID: 29723705
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 antiretroviral resistance: scientific principles and clinical applications.
Tang MW; Shafer RW
Drugs; 2012 Jun; 72(9):e1-25. PubMed ID: 22686620
[TBL] [Abstract][Full Text] [Related]
9. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
10. Fully synthetic injectable depots with high drug content and tunable pharmacokinetics for long-acting drug delivery.
Ho DK; LeGuyader C; Srinivasan S; Roy D; Vlaskin V; Chavas TEJ; Lopez CL; Snyder JM; Postma A; Chiefari J; Stayton PS
J Control Release; 2021 Jan; 329():257-269. PubMed ID: 33217474
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and characterization of a long-acting emtricitabine prodrug nanoformulation.
Ibrahim IM; Bade AN; Lin Z; Soni D; Wojtkiewicz M; Dyavar Shetty BL; Gautam N; McMillan JM; Alnouti Y; Edagwa BJ; Gendelman HE
Int J Nanomedicine; 2019; 14():6231-6247. PubMed ID: 31496683
[TBL] [Abstract][Full Text] [Related]
12. Antiretroviral agents in pre-exposure prophylaxis: emerging and advanced trends in HIV prevention.
Yap PK; Loo Xin GL; Tan YY; Chellian J; Gupta G; Liew YK; Collet T; Dua K; Chellappan DK
J Pharm Pharmacol; 2019 Sep; 71(9):1339-1352. PubMed ID: 31144296
[TBL] [Abstract][Full Text] [Related]
13. Long-acting parenteral combination antiretroviral loaded nano-drug delivery system to treat chronic HIV-1 infection: A humanized mouse model study.
Mandal S; Kang G; Prathipati PK; Fan W; Li Q; Destache CJ
Antiviral Res; 2018 Aug; 156():85-91. PubMed ID: 29885378
[TBL] [Abstract][Full Text] [Related]
14. Polymer-prodrug conjugates as candidates for degradable, long-acting implants, releasing the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine.
Liu C; Hern FY; Shakil A; Temburnikar K; Chambon P; Liptrott N; McDonald TO; Neary M; Flexner C; Owen A; Meyers CF; Rannard SP
J Mater Chem B; 2023 Dec; 11(48):11532-11543. PubMed ID: 37955203
[TBL] [Abstract][Full Text] [Related]
15. Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission.
Mandal S; Kang G; Prathipati PK; Zhou Y; Fan W; Li Q; Destache CJ
J Control Release; 2019 Jan; 294():216-225. PubMed ID: 30576746
[TBL] [Abstract][Full Text] [Related]
16. Long-acting slow effective release antiretroviral therapy.
Edagwa B; McMillan J; Sillman B; Gendelman HE
Expert Opin Drug Deliv; 2017 Nov; 14(11):1281-1291. PubMed ID: 28128004
[TBL] [Abstract][Full Text] [Related]
17. Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study.
Pedrol E; Caro-Murillo AM; Castaño MA; Riera M; Olalla J; Domingo P; Arazo P; Gómez-Sirvent JL; Pulido F; Romero-Palacios A; Aguirrebengoa K; Vera F; Ferrer P; Blanco Ramos JR
HIV Clin Trials; 2015; 16(1):43-8. PubMed ID: 25777189
[TBL] [Abstract][Full Text] [Related]
18. Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.
Bazzoli C; Jullien V; Le Tiec C; Rey E; Mentré F; Taburet AM
Clin Pharmacokinet; 2010; 49(1):17-45. PubMed ID: 20000887
[TBL] [Abstract][Full Text] [Related]
19. Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial.
Duvivier C; Ghosn J; Assoumou L; Soulié C; Peytavin G; Calvez V; Génin MA; Molina JM; Bouchaud O; Katlama C; Costagliola D;
J Antimicrob Chemother; 2008 Oct; 62(4):797-808. PubMed ID: 18641035
[TBL] [Abstract][Full Text] [Related]
20. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
